{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:15:11Z","timestamp":1788326111523,"version":"build-2803163510"},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acne remains as the most common skin disease in the United States even despite multiple approved topical and systemic medications available. These treatments available over the counter and by prescription can be classified based on comedolytic, antibacterial and anti\u2010inflammatory activities and are often used in combination. Therefore, understanding of the mechanism of action is critical to achieving the best clinical outcome and synergy. One of the newer acne medications with historical data suggesting both antibacterial and anti\u2010inflammatory activity is dapsone. In order to gain mechanistic insight into the anti\u2010inflammatory activity of dapsone in <jats:italic>Propionibacterium<\/jats:italic> (a former genus name recently reclassified as \u201c<jats:italic>Cutibacterium<\/jats:italic>\u201d) (<jats:italic>P.\u00a0acnes<\/jats:italic>)<jats:italic>\u2010<\/jats:italic>driven inflammation, we used two human in vitro models: primary human neonatal epidermal keratinocytes and human monocytes (<jats:styled-content style=\"fixed-case\">THP<\/jats:styled-content>\u20101). We demonstrate that dapsone suppresses production of specific cytokine signatures interleukin (<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>)1\u03b1 and <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>8 in human epidermal keratinocytes and <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>1\u03b2, <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>6, <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>8 and tumor necrosis factor\u2010\u03b1 in <jats:styled-content style=\"fixed-case\">THP<\/jats:styled-content>\u20101 cells in response to <jats:italic>P.\u00a0acnes<\/jats:italic>. Using <jats:styled-content style=\"fixed-case\">THP<\/jats:styled-content>\u20101 cell in vitro model, we show that <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>1\u03b2 and <jats:styled-content style=\"fixed-case\">CASP<\/jats:styled-content>\u20101 are regulated by dapsone independently of <jats:styled-content style=\"fixed-case\">NF<\/jats:styled-content>\u03baB activity at transcriptional and post\u2010transcriptional levels, respectively.<\/jats:p>","DOI":"10.1111\/exd.13869","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T12:33:29Z","timestamp":1545827609000},"page":"190-197","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mechanistic insight into the activity of a sulfone compound dapsone on <i>Propionibacterium<\/i> (Newly Reclassified as <i>Cutibacterium<\/i>) <i>Acnes\u2010<\/i>mediated cytokine production"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8813-4710","authenticated-orcid":false,"given":"Mikhail","family":"Geyfman","sequence":"first","affiliation":[{"name":"Allergan plc  Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Debabov","sequence":"additional","affiliation":[{"name":"Allergan plc  Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Poloso","sequence":"additional","affiliation":[{"name":"Allergan plc  Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Alvandi","sequence":"additional","affiliation":[{"name":"Allergan plc  Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,29]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"94","volume":"86","author":"Yentzer B. A.","year":"2010","journal-title":"Cutis"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1099\/ijsem.0.001367"},{"key":"e_1_2_8_4_1","first-page":"582","volume":"10","author":"Bellew S.","year":"2011","journal-title":"J. Drugs Dermatol."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2004.05762.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363150-00005"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(02)00013-0"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.528"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.438"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-013-1409-7"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.2.456"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(92)90449-S"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.62.6.827"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06559.x"},{"key":"e_1_2_8_15_1","first-page":"474","volume":"10","author":"Scheinfeld N.","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.221"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.309"},{"key":"e_1_2_8_18_1","first-page":"3","volume":"81","author":"Thiboutot D. M.","year":"2008","journal-title":"Cutis"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2000.00739.x"},{"key":"e_1_2_8_20_1","first-page":"123","volume":"53","author":"Barr J.","year":"2011","journal-title":"Pharm. Hist."},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5070\/D330M4B5KR","volume":"8","author":"Wolf R.","year":"2002","journal-title":"Dermatol. Online J."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903002097"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12555654"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.62.6.827"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fexd.13869","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.13869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T10:14:15Z","timestamp":1694686455000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/exd.13869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1111\/exd.13869"],"URL":"https:\/\/doi.org\/10.1111\/exd.13869","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,29]]},"assertion":[{"value":"2018-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}